LUCIDITY phase 3 topline data presented at CTAD for HMTM – the only oral anti-Tau therapy in late-stage development
- Tau aggregation inhibitor, HMTM, is an oral drug with a strong safety profile, having no risk of amyloid related imaging abnormalities - Topline results for the Phase 3 study, LUCIDITY, were shared at the Clinical Trials in Alzheimer's Disease (CTAD) conference on Wednesday, 30th November 2022, in San Francisco - For people with early Alzheimer's (MCI), HMTM improvement...
Menarini Group Presents Updated Results from Pivotal Phase 3 EMERALD Trial at the 2022 San Antonio Breast Cancer Symposium (SABCS) that Demonstrate Elacestrant’s PFS Increases with Duration of Prior...
Elacestrant demonstrated longer progression-free survival (PFS) vs SOC endocrine therapy with medians up to 8.6 months, positively associated with the duration of prior treatment with CDK4/6 inhibitors Elacestrant side effects were manageable and consistent with previously reported results Results demonstrate that elacestrant may have the potential to become a new standard of care as...
S3 Connected Health Receives Frost & Sullivan’s Award for Helping Medical Device Companies Create Custom Connected Medical Device Solutions
S3 Connected Health supports its partners and clients by defining optimal solutions that address their unique needs and constraints, taking customers from concept to development, operation, and lifecycle management SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- Recently, Frost & Sullivan analyzed the global medical device connectivity industry and, based on its research findings, recognizes S3 Connected Health with the...
Prenetics Announces US$20 Million Stock Repurchase Program and Inclusion into the MSCI Global Micro Cap Index
LONDON and HONG KONG, Nov. 30, 2022 /PRNewswire/ -- Prenetics Global Limited (NASDAQ: PRE) ("Prenetics" or the "Company"), a global leader in genomic and diagnostic testing, today announced that its board of directors has authorized a share repurchase program, and that it has been included as a constituent stock in the MSCI Global Micro Cap Index (Hong Kong), with...
TIANGEN to Roll out a Stunning Automated Solution at Cell Bio 2022
WASHINGTON, Nov. 30, 2022 /PRNewswire/ -- TIANGEN, a leading brand in the field of nucleic acid purification in China, has announced its participation in the Cell Bio 2022, the joint meeting of the American Society for Cell Biology (ASCB) and European Molecular Biology Organization (EMBO), from December 4 to 6, in Washington, DC, where it will bring a groundbreaking...
Ascletis Announces Completion of 180 Patient Enrollment for Phase II Clinical Trial of FASN Inhibitor ASC40 for Acne
--To date, approximately 50% enrolled patients have completed 12-week treatment and all enrolled patients are expected to complete 12-week treatment by the end of February 2023 -- Clinical efficacy observed in patients who have completed 12-week treatment of ASC40 or placebo was comparable to that from two U.S. FDA approved acne drugs - WINLEVI® and TWYNEO® --In the...
Kira Pharmaceuticals Announces First Cohort of Patients Dosed in Phase 2 Study of KP104 in Paroxysmal Nocturnal Hemoglobinuria (PNH)
CAMBRIDGE, Mass., Nov. 30, 2022 /PRNewswire/ -- Kira Pharmaceuticals, a global biotechnology company pioneering transformational complement therapies to treat immune-mediated diseases, today announced that the first cohort has been dosed in a Phase 2 trial evaluating KP104 for the treatment of paroxysmal nocturnal hemoglobinuria (PNH) in patients in China. KP104 is a first-in-class...
Cardiac Troponin Diagnostics Market Growth Boosted by High-sensitivity Point-of-care Testing
The rise in emergency department visits due to cardiac complaints drives the demand for cTn biomarkers SAN ANTONIO, Nov. 30, 2022 /PRNewswire/ -- The global demand for cardiac troponin (cTn) diagnostics biomarkers is increasing as more patients with cardiac complaints are visiting emergency departments (EDs), according to Frost & Sullivan's recent analysis of the cTn diagnostics market. The...
Global alliance of heart patient organizations unveils new Global Cholesterol Action Plan to prioritize unhealthy cholesterol as a main public health issue
GALWAY, Ireland, Nov. 30, 2022 /PRNewswire/ -- The Global Heart Hub has today launched its Global Cholesterol Action Plan to reduce the impact of unhealthy cholesterol levels . Presented at their annual UNITE Summit , the Action Plan follows and builds upon the World Heart Federation's Cholesterol Roadmap released in October. Atherosclerotic cardiovascular disease...
Navigating a perfect storm – driving access to healthcare in emerging markets
Healthcare demand and expenditure in Southeast Asia are set to increase rapidly amidst rising affluence and an ageing population Emerging markets comprise 60% of the global population but contribute only 20% of global healthcare spending, highlighting the issue of equitable access An innovative collaborative approach is key to bridging and addressing unmet medical needs in the region, says...
